<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Investigational anticoagulants
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Investigational anticoagulants
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Investigational anticoagulants
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jeffrey I Weitz, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Kenneth A Bauer, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jennifer S Tirnauer, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Aug 17, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1083099129">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Anticoagulants in clinical use have advantages and disadvantages related to their efficacy profile, safety, route of administration, drug interactions, and cost. All available anticoagulants increase bleeding to some degree. Strategies for developing safer and more effective anticoagulants continue to be pursued.
        </p>
        <p>
         Development of new anticoagulants often starts with dose-finding studies in patients undergoing elective knee arthroplasty; efficacy can be objectively and efficiently assessed in such patients using venography to determine the rate of deep vein thrombosis after surgery. Such information can then be used to inform dosing for other therapeutic indications.
        </p>
        <p>
         This topic discusses anticoagulants at later stages of development for clinical use. Approved anticoagulants are discussed in separate topic reviews.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Parenteral
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Heparins – (See
         <a class="medical medical_review" href="/z/d/html/1348.html" rel="external">
          "Heparin and LMW heparin: Dosing and adverse effects"
         </a>
         .)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">
          Fondaparinux
         </a>
         – (See
         <a class="medical medical_review" href="/z/d/html/1319.html" rel="external">
          "Fondaparinux: Dosing and adverse effects"
         </a>
         .)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="8765" href="/z/d/drug information/8765.html" rel="external">
          Argatroban
         </a>
         and
         <a class="drug drug_general" data-topicid="8792" href="/z/d/drug information/8792.html" rel="external">
          bivalirudin
         </a>
         – (See
         <a class="medical medical_review" href="/z/d/html/1370.html" rel="external">
          "Direct oral anticoagulants (DOACs) and parenteral direct-acting anticoagulants: Dosing and adverse effects", section on 'Parenteral direct thrombin inhibitors'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Oral
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Vitamin K antagonists – (See
         <a class="medical medical_review" href="/z/d/html/1334.html" rel="external">
          "Warfarin and other VKAs: Dosing and adverse effects"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1337.html" rel="external">
          "Biology of warfarin and modulators of INR control"
         </a>
         .)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="8926" href="/z/d/drug information/8926.html" rel="external">
          Dabigatran
         </a>
         – (See
         <a class="medical medical_review" href="/z/d/html/1370.html" rel="external">
          "Direct oral anticoagulants (DOACs) and parenteral direct-acting anticoagulants: Dosing and adverse effects", section on 'Dabigatran'
         </a>
         .)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Factor Xa inhibitors – (See
         <a class="medical medical_review" href="/z/d/html/1370.html" rel="external">
          "Direct oral anticoagulants (DOACs) and parenteral direct-acting anticoagulants: Dosing and adverse effects", section on 'Direct factor Xa inhibitors'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2451202371">
         <span class="h1">
          INHIBITORS OF FACTOR XI OR FACTOR XIa
         </span>
         <span class="headingEndMark">
          —
         </span>
         Factor XI is part of the intrinsic pathway of the clotting cascade; the activated form (factor XIa) participates in the amplification of thrombin generation (
         <a class="graphic graphic_figure graphicRef90873" href="/z/d/graphic/90873.html" rel="external">
          figure 1
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/1371.html" rel="external">
          "Overview of hemostasis", section on 'Intrinsic or contact activation pathway'
         </a>
         .)
        </p>
        <p>
         Individuals with hereditary factor XI deficiency have a lower risk of venous thromboembolism (VTE) or ischemic stroke than individuals with normal factor XI levels but rarely have spontaneous bleeding. (See
         <a class="medical medical_review" href="/z/d/html/1333.html" rel="external">
          "Factor XI (eleven) deficiency"
         </a>
         .)
        </p>
        <p>
         It has been hypothesized that inhibition of factor XI/XIa, by blocking the amplification of thrombin generation, might uncouple thrombosis prevention from normal hemostasis, allowing maximal anticoagulation without incurring more bleeding risk.
        </p>
        <p class="headingAnchor" id="H416832368">
         <span class="h2">
          Milvexian
         </span>
         <span class="headingEndMark">
          —
         </span>
         Milvexian is an orally active, potent and specific small molecule inhibitor of factor XIa [
         <a href="#rid1">
          1,2
         </a>
         ]. In a trial that randomly assigned 1242 individuals ≥50 years who were undergoing knee arthroplasty to receive one of several doses/schedules of milvexian versus low molecular weight (LMW) heparin (
         <a class="drug drug_general" data-topicid="9407" href="/z/d/drug information/9407.html" rel="external">
          enoxaparin
         </a>
         40 mg once daily) for 10 to 14 days postoperatively, participants assigned to milvexian had lower rates of VTE [
         <a href="#rid3">
          3
         </a>
         ]. All participants underwent mandatory unilateral venography on the operated leg 10 to 14 days after surgery.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Efficacy
         </strong>
         – There was a dose-dependent reduction in postoperative VTE rates with once or twice daily milvexian:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Milvexian, 25 mg once daily – 25 percent
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Milvexian, 25 mg twice daily – 21 percent
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Milvexian, 50 mg twice daily – 11 percent
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Milvexian, 100 mg twice daily – 9 percent
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Milvexian, 200 mg once daily – 7 percent
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Milvexian, 200 mg twice daily – 8 percent
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="9407" href="/z/d/drug information/9407.html" rel="external">
          Enoxaparin
         </a>
         , 40 mg once daily – 21 percent
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Safety
         </strong>
         – Bleeding rates (a composite of major, clinically relevant nonmajor, and minor bleeding) were similar (4 percent with milvexian and 4 percent with
         <a class="drug drug_general" data-topicid="9407" href="/z/d/drug information/9407.html" rel="external">
          enoxaparin
         </a>
         ). Major bleeding occurred in one individual in the enoxaparin arm and none in the milvexian arm. Rates of clinically relevant bleeding (a composite of major and clinically relevant nonmajor bleeding) were 0.8 percent with milvexian and 1.7 percent with enoxaparin. There was no dose-dependent increase in the rate of clinically relevant bleeding over a 16-fold range of milvexian doses.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1648396272">
         <span class="h2">
          Asundexian
         </span>
         <span class="headingEndMark">
          —
         </span>
         Asundexian is an orally active, potent, and specific small molecule inhibitor of factor XIa [
         <a href="#rid4">
          4-6
         </a>
         ]. In a trial that randomly assigned 753 individuals with atrial fibrillation (mean age, 74 years; nearly one-third had chronic kidney disease) to receive asundexian (20 or 50 mg once daily) or the factor Xa inhibitor
         <a class="drug drug_general" data-topicid="85642" href="/z/d/drug information/85642.html" rel="external">
          apixaban
         </a>
         (5 mg twice daily) for 12 weeks, participants assigned to asundexian had similar or lower rates of clinical bleeding compared with those assigned to apixaban [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Efficacy
         </strong>
         – Efficacy for stroke prevention was not a primary endpoint during this short observation period. Rates of a composite endpoint of cardiovascular death, myocardial infarction, stroke, or embolism were:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Asundexian 20 mg once daily – 0.8 percent
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Asundexian 50 mg once daily – 1.5 percent
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="85642" href="/z/d/drug information/85642.html" rel="external">
          Apixaban
         </a>
         5 mg twice daily – 1.2 percent
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Safety
         </strong>
         – There were no episodes of major bleeding. Clinically relevant nonmajor bleeding rates were as follows:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Asundexian 20 mg once daily – 1.2 percent
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Asundexian 50 mg once daily – 0.4 percent
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="85642" href="/z/d/drug information/85642.html" rel="external">
          Apixaban
         </a>
         5 mg twice daily – 2.4 percent
        </p>
        <p>
        </p>
        <p>
         A randomized trial of asundexian 20 or 50 mg in 1601 individuals with acute myocardial infarction assigned to secondary prevention with asundexian or placebo found similar rates of stroke, cardiovascular events, and stent thrombosis with asundexian and placebo and no increase in bleeding with asundexian [
         <a href="#rid8">
          8
         </a>
         ]. Nearly all participants underwent percutaneous intervention and all received dual antiplatelet therapy. A randomized trial of asundexian in 1808 individuals with prior ischemic (non-embolic) stroke showed no difference in stroke incidence or bleeding (risk of covert brain infarct or recurrent stroke in approximately 19 percent of individuals assigned to asundexian and placebo [
         <a href="#rid9">
          9
         </a>
         ]).
        </p>
        <p class="headingAnchor" id="H2535297177">
         <span class="h2">
          Abelacimab
         </span>
         <span class="headingEndMark">
          —
         </span>
         Abelacimab (MAA868) is a monoclonal antibody that binds to factor XI (the inactive precursor) and locks it in the inactive state, preventing it from being activated by factor XIIa or thrombin. A trial involving 412 individuals undergoing knee arthroplasty evaluated three doses of abelacimab (30, 75, or 150 mg) administered postoperatively as a single intravenous infusion versus subcutaneous
         <a class="drug drug_general" data-topicid="9407" href="/z/d/drug information/9407.html" rel="external">
          enoxaparin
         </a>
         , 40 mg once daily [
         <a href="#rid10">
          10
         </a>
         ]. Patients could receive a single preoperative dose of enoxaparin. All participants underwent postoperative venography for VTE evaluation. There was a lower rate of VTE with all doses of abelacimab than with enoxaparin.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Efficacy
         </strong>
         – Postoperative VTE rates were as follows:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Abelacimab, 30 mg – 13 percent
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Abelacimab, 75 mg – 5 percent
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Abelacimab, 150 mg – 4 percent
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="9407" href="/z/d/drug information/9407.html" rel="external">
          Enoxaparin
         </a>
         , 40 mg – 22 percent
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Safety
         </strong>
         – The risk of clinically relevant bleeding (the composite of major and clinically relevant nonmajor bleeding) was low (2, 2, and 0 percent of patients in the 30, 75, and 150 mg abelacimab cohorts, and in 0 percent of those treated with
         <a class="drug drug_general" data-topicid="9407" href="/z/d/drug information/9407.html" rel="external">
          enoxaparin
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1259250231">
         <span class="h2">
          Osocimab
         </span>
         <span class="headingEndMark">
          —
         </span>
         Osocimab (BAY 1213790) is a monoclonal antibody that binds adjacent to the active site of factor XIa and prevents it from activating factor IX (allosteric inhibition) [
         <a href="#rid11">
          11
         </a>
         ]. The half-life of osocimab is 30 to 44 days, allowing single-dose administration for surgical prophylaxis. It is administered as an intravenous infusion over one hour.
        </p>
        <p>
         A trial evaluated dose-finding, timing of administration, and comparison with other anticoagulants (
         <a class="drug drug_general" data-topicid="9407" href="/z/d/drug information/9407.html" rel="external">
          enoxaparin
         </a>
         and
         <a class="drug drug_general" data-topicid="85642" href="/z/d/drug information/85642.html" rel="external">
          apixaban
         </a>
         ) in 813 adults undergoing elective knee arthroplasty [
         <a href="#rid12">
          12
         </a>
         ]. Individuals were randomly assigned to receive one of several weight-based doses of osocimab, some preoperatively and some postoperatively, or to receive enoxaparin (40 mg subcutaneously twice daily started the evening before surgery or 12 to 24 hours postoperatively) or apixaban (2.5 mg orally twice per day starting 12 to 24 hours postoperatively).
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Efficacy
         </strong>
         – The risk of VTE (symptomatic or identified by mandatory screening venography) was lowest in individuals who received the highest osocimab dose (1.8 mg/kg), given preoperatively (11.3 percent), followed by
         <a class="drug drug_general" data-topicid="85642" href="/z/d/drug information/85642.html" rel="external">
          apixaban
         </a>
         (14.5 percent). VTE rates were 26.3 percent with
         <a class="drug drug_general" data-topicid="9407" href="/z/d/drug information/9407.html" rel="external">
          enoxaparin
         </a>
         and 15.7 to 17.9 with various doses of osocimab given postoperatively. In all the arms, most of the VTE events were asymptomatic; symptomatic VTE occurred in 0 to 2 percent of participants.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Safety
         </strong>
         – The risk of major bleeding was 1 to 5 percent with osocimab (depending on dose and timing), 6 percent with
         <a class="drug drug_general" data-topicid="9407" href="/z/d/drug information/9407.html" rel="external">
          enoxaparin
         </a>
         , and 2 percent with
         <a class="drug drug_general" data-topicid="85642" href="/z/d/drug information/85642.html" rel="external">
          apixaban
         </a>
         . All bleeding events were surgical site bleeding; there were no instances of intracranial or other critical sites of bleeding. Thrombocytopenia was seen in 6 percent of the osocimab and enoxaparin-treated patients and 2 percent of the apixaban-treated patients.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2955965142">
         <span class="h2">
          Fesomersen
         </span>
         <span class="headingEndMark">
          —
         </span>
         Fesomersen is a ligand conjugated factor XI antisense oligonucleotide (ASO) that blocks synthesis of factor XI in the liver, thereby reducing the circulating levels of factor XI [
         <a href="#rid13">
          13
         </a>
         ].
        </p>
        <p>
         In an open-label trial, 300 patients undergoing elective knee replacement were randomly assigned to receive the first generation, nonligand conjugated ASO at one of two doses (200 or 300 mg) or
         <a class="drug drug_general" data-topicid="9407" href="/z/d/drug information/9407.html" rel="external">
          enoxaparin
         </a>
         (40 mg) once daily [
         <a href="#rid14">
          14
         </a>
         ]. The rate of VTE, assessed by venography in all patients, was reduced in those receiving the higher dose of ASO (3 of 71 patients; 4 percent), compared with the lower dose of ASO (27 percent) or enoxaparin (30 percent). Bleeding was not increased with the higher ASO dose (3 percent), versus 3 percent for ASO 200 mg and 8 percent for enoxaparin (
         <a class="graphic graphic_figure graphicRef90873" href="/z/d/graphic/90873.html" rel="external">
          figure 1
         </a>
         ).
        </p>
        <p>
         There are caveats for this strategy including the extended half-life of the antisense therapy (up to three months), injection site reactions, and potential cost [
         <a href="#rid15">
          15
         </a>
         ]. Fesomersen, the second-generation ligand-conjugated antisense oligonucleotide, has increased potency, thereby reducing the required volume of injection and the risk of injection site reactions, and likely decreasing cost.
        </p>
        <p class="headingAnchor" id="H3021882485">
         <span class="h2">
          AB023
         </span>
         <span class="headingEndMark">
          —
         </span>
         ABO23 is a monoclonal antibody that binds to factor XI and prevents its activation by factor XIIa, thus acting as a factor XIIa inhibitor [
         <a href="#rid16">
          16
         </a>
         ]. By leaving intact the activation of factor XI by thrombin, this agent may allow better separation of thrombosis from hemostasis.
        </p>
        <p class="headingAnchor" id="H485817124">
         <span class="h2">
          Sulfated chiro-inositol
         </span>
         <span class="headingEndMark">
          —
         </span>
         Sulfated chiro-inositol (SCI) is a synthetic heparin-like molecule that binds to factor XIa and alters its conformation, thereby reducing its enzymatic activity (allosteric inhibition) [
         <a href="#rid17">
          17
         </a>
         ]. Preclinical testing suggests that this molecule could be effective as an anticoagulant and could be reversed by
         <a class="drug drug_general" data-topicid="9831" href="/z/d/drug information/9831.html" rel="external">
          protamine sulfate
         </a>
         .
        </p>
        <p class="headingAnchor" id="H3867455581">
         <span class="h1">
          INHIBITORS OF OTHER CLOTTING PROTEINS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Other coagulation proteins involved in thrombosis are amenable to inhibition. (See
         <a class="medical medical_review" href="/z/d/html/1371.html" rel="external">
          "Overview of hemostasis"
         </a>
         .)
        </p>
        <p>
         Although many agents have been investigated, none have moved forward into advanced stages of development.
        </p>
        <p class="headingAnchor" id="H3168196000">
         <span class="h2">
          TF/factor VIIa inhibitors
         </span>
         <span class="headingEndMark">
          —
         </span>
         Vascular injury causes exposure of tissue factor (TF). TF binds activated factor VII (factor VIIa) and promote activation of factor X; this is the extrinsic pathway of the clotting cascade. (See
         <a class="medical medical_review" href="/z/d/html/1371.html" rel="external">
          "Overview of hemostasis", section on 'Extrinsic pathway'
         </a>
         .)
        </p>
        <p>
         Inhibitors of the TF pathway could potentially be developed as anticoagulants.
        </p>
        <p>
         Conversely, natural inhibitors of the TF pathway, such as tissue factor pathway inhibitor (TFPI), antithrombin, and activated protein C, could potentially render the TF pathway more active. Approaches that take advantage of these steps in the clotting cascade are under investigation as "rebalancing therapies" to reduce bleeding risk in people with hemophilia. (See
         <a class="medical medical_review" href="/z/d/html/1371.html" rel="external">
          "Overview of hemostasis", section on 'Control mechanisms and termination of clotting'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/134290.html" rel="external">
          "Gene therapy and other investigational approaches for hemophilia", section on 'Reducing natural anticoagulants'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H173994416">
         <span class="h3">
          Recombinant TFPI and anti-TF antibodies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Tissue factor pathway inhibitor (TFPI) is the physiologic inhibitor of the TF-FVIIa complex. Recombinant TFPI, anti-TF monoclonal antibodies, and peptide inhibitors of TF were investigated as anticoagulants, but development of these agents has stopped [
         <a href="#rid18">
          18,19
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1082800598">
         <span class="h3">
          Nematode anticoagulant peptide-2 (NAPc2)
         </span>
         <span class="headingEndMark">
          —
         </span>
         NAPc2 is a peptide produced by a hookworm nematode; it blocks the TF-factor VIIa complex. Recombinant NAPc2 is a potential anticoagulant [
         <a href="#rid20">
          20-22
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3778962635">
         <span class="h2">
          Factor VIII inhibitor
         </span>
         <span class="headingEndMark">
          —
         </span>
         Factor VIIIa acts as a nonenzymatic cofactor for factor IXa in activating factor X (the "intrinsic tenase" complex). (See
         <a class="medical medical_review" href="/z/d/html/1371.html" rel="external">
          "Overview of hemostasis", section on 'Multicomponent complexes'
         </a>
         .)
        </p>
        <p>
         TB-402 is a human IgG4 monoclonal antibody that partially inhibits factor VIII. The long half-life (approximately three weeks) suggested that the therapy might be effective as a single dose.
        </p>
        <p>
         In a randomized phase II trial in patients after total knee replacement, a single postoperative intravenous dose of TB-402 was more effective than the low molecular weight (LMW) heparin
         <a class="drug drug_general" data-topicid="9407" href="/z/d/drug information/9407.html" rel="external">
          enoxaparin
         </a>
         (40 mg/day for at least 10 days) in preventing postoperative venous thromboembolism (VTE) [
         <a href="#rid23">
          23
         </a>
         ]. However, bleeding rates with TB-402 were higher than with enoxaparin (major or clinically relevant nonmajor bleeding, 4.0, 5.4, and 8.0 percent with 0.3, 0.6, and 1.2 mg/kg of TB-402 compared with 3.8 percent with enoxaparin). Consequently, further development of TB-402 was halted.
        </p>
        <p class="headingAnchor" id="H1995682409">
         <span class="h2">
          Thrombomodulin
         </span>
         <span class="headingEndMark">
          —
         </span>
         Thrombomodulin is a membrane protein that acts as a cofactor for thrombin in activating protein C [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p>
         A recombinant form of the extracellular domain of thrombomodulin was developed as an anticoagulant (ART-123) and has been approved in Japan for treatment of disseminated intravascular coagulation (DIC). It has a half-life of two to three days after a subcutaneous injection, such that it can be given once every five to six days with maintenance of anticoagulant activity [
         <a href="#rid25">
          25
         </a>
         ]. In a phase II trial, ART-123 was effective for VTE prophylaxis following total hip replacement [
         <a href="#rid26">
          26
         </a>
         ]. However, ART-123 has not progressed further for prevention or treatment of VTE.
        </p>
        <p class="headingAnchor" id="H1300043882">
         <span class="h2">
          Factor IXa inhibitor
         </span>
         <span class="headingEndMark">
          —
         </span>
         REG1 consists of pegnivacogin (RB006), an injectable ribonucleic acid (RNA) aptamer that specifically binds and inhibits factor IXa, and anivamersen (RB007), the complementary oligonucleotide that neutralizes its anti-IXa activity when needed (ie, as an antidote).
        </p>
        <p>
         Initial tests of this agent combined with antiplatelet therapy in patients with coronary artery disease appeared promising [
         <a href="#rid27">
          27,28
         </a>
         ]. However, a randomized trial comparing REG1 with
         <a class="drug drug_general" data-topicid="8792" href="/z/d/drug information/8792.html" rel="external">
          bivalirudin
         </a>
         in patients undergoing percutaneous coronary intervention (PCI) was terminated early due to severe allergic reactions (including fatal reactions) with REG1 in 10 of 1616 patients (1 percent), compared with 1 of 1616 patients (0.1 percent) given bivalirudin [
         <a href="#rid29">
          29
         </a>
         ]. Consequently, further development of REG1 was halted.
        </p>
        <p class="headingAnchor" id="H685408000">
         <span class="h2">
          Factor XIIa inhibitor
         </span>
         <span class="headingEndMark">
          —
         </span>
         Factor XIIa is the initial enzyme in the intrinsic pathway of the coagulation cascade. (See
         <a class="medical medical_review" href="/z/d/html/1371.html" rel="external">
          "Overview of hemostasis", section on 'Intrinsic or contact activation pathway'
         </a>
         .)
        </p>
        <p>
         Infestin-4 is a factor XIIa inhibitor produced by a blood-feeding insect. Recombinant Infestin-4 fused to albumin (rHA-Infestin-4) is highly active as an anticoagulant in preclinical studies (human plasma and animal models) [
         <a href="#rid30">
          30
         </a>
         ]. rHA-Infestin-4 is being considered for prevention and treatment of acute ischemic cardiovascular and cerebrovascular events.
        </p>
        <p class="headingAnchor" id="H1401254509">
         <span class="h2">
          Protein disulfide isomerase inhibitors
         </span>
         <span class="headingEndMark">
          —
         </span>
         Protein disulfide isomerase (PDI) is an oxidoreductase enzyme that catalyzes redox protein folding in newly synthesized proteins in the endoplasmic reticulum, including coagulation factor XI and tissue factor. PDI is expressed on the surface of several cell types, including platelets, where it promotes platelet aggregation via integrin activation [
         <a href="#rid31">
          31
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1371.html" rel="external">
          "Overview of hemostasis", section on 'Platelet secretion'
         </a>
         .)
        </p>
        <p>
         PDI inhibitors have the potential to attenuate thrombin generation and platelet activation. Several molecules inhibit PDI, including quercetins, which are found in certain plant-based foods. Preclinical studies using a peptide inhibitor of PDI have demonstrated antiplatelet activity in vitro [
         <a href="#rid32">
          32
         </a>
         ]. In a phase 2 trial in patients with cancer who were at risk for VTE, isoquercetin (1000 mg daily, but not 500 mg) decreased plasma D-dimer levels by 22 percent [
         <a href="#rid33">
          33
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1864398958">
         <span class="h2">
          Polyphosphate inhibitors
         </span>
         <span class="headingEndMark">
          —
         </span>
         Polyphosphate (released from platelets upon their activation or from a microbial source) may initiate and/or accelerate coagulation via the intrinsic pathway. Compounds that inhibit polyphosphate and reduce thrombosis in preclinical models are under investigation [
         <a href="#rid34">
          34
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3955035868">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/114614.html" rel="external">
          "Society guideline links: Anticoagulation"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H126981338">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Factor XI/XIa inhibitors
         </strong>
         – Factor XI is part of the intrinsic pathway of the clotting cascade; activated factor XI (factor XIa) participates in amplifying thrombin generation (
         <a class="graphic graphic_figure graphicRef90873" href="/z/d/graphic/90873.html" rel="external">
          figure 1
         </a>
         ). It has been hypothesized that inhibition of factor XI/XIa might uncouple thrombosis prevention from normal hemostasis, allowing maximal anticoagulation without increasing bleeding risk. (See
         <a class="medical medical_review" href="/z/d/html/1371.html" rel="external">
          "Overview of hemostasis", section on 'Intrinsic or contact activation pathway'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Several factor XI or XIa inhibitors are under development, including small molecules (ending in "xian") and monoclonal antibodies (ending in "mab") and an antisense oligonucleotide (fesomersen):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Milvexian – (See
         <a class="local">
          'Milvexian'
         </a>
         above.)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Asundexian – (See
         <a class="local">
          'Asundexian'
         </a>
         above.)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Abelacimab – (See
         <a class="local">
          'Abelacimab'
         </a>
         above.)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Osocimab – (See
         <a class="local">
          'Osocimab'
         </a>
         above.)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Fesomersen – (See
         <a class="local">
          'Fesomersen'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          TF-factor VIIa inhibitors
         </strong>
         – Vascular injury causes tissue factor (TF) exposure. TF binds activated factor VII (factor VIIa) and promotes activation of factor X; this is the extrinsic pathway of the clotting cascade. (See
         <a class="medical medical_review" href="/z/d/html/1371.html" rel="external">
          "Overview of hemostasis", section on 'Extrinsic pathway'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Inhibitors of the TF-factor VIIa pathway are being explored, including recombinant tissue factor pathway inhibitor (TFPI) and peptides derived from nematodes:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Recombinant TFPI – (See
         <a class="local">
          'Recombinant TFPI and anti-TF antibodies'
         </a>
         above.)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Nematode anticoagulant peptide-2 (NAPc2) – (See
         <a class="local">
          'Nematode anticoagulant peptide-2 (NAPc2)'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Earlier stages of development
         </strong>
         – Inhibitors of thrombomodulin, factor XIIa, and protein disulfide isomerase (PDI) are under development. (See
         <a class="local">
          'Thrombomodulin'
         </a>
         above and
         <a class="local">
          'Factor XIIa inhibitor'
         </a>
         above and
         <a class="local">
          'Protein disulfide isomerase inhibitors'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Development halted
         </strong>
         – Development of some anticoagulants has been halted due to increased bleeding (factor VIII inhibitor) or excessive adverse effects (anaphylaxis with factor IXa inhibitor REG1). (See
         <a class="local">
          'Factor VIII inhibitor'
         </a>
         above and
         <a class="local">
          'Factor IXa inhibitor'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Perera V, Wang Z, Luettgen J, et al. First-in-human study of milvexian, an oral, direct, small molecule factor XIa inhibitor. Clin Transl Sci 2022; 15:330.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Perera V, Wang Z, Lubin S, et al. Safety, pharmacokinetics, and pharmacodynamics of milvexian in healthy Japanese participants. Sci Rep 2022; 12:5165.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weitz JI, Strony J, Ageno W, et al. Milvexian for the Prevention of Venous Thromboembolism. N Engl J Med 2021; 385:2161.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thomas D, Kanefendt F, Schwers S, et al. First evaluation of the safety, pharmacokinetics, and pharmacodynamics of BAY 2433334, a small molecule targeting coagulation factor XIa. J Thromb Haemost 2021; 19:2407.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mailer RK, Renné T. Commentary on "Pharmacological profile of asundexian, a novel, orally bioavailable inhibitor of factor XIa": Small molecule factor XIa inhibitor asundexian allows for safer anticoagulation. J Thromb Haemost 2022; 20:1309.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heitmeier S, Visser M, Tersteegen A, et al. Pharmacological profile of asundexian, a novel, orally bioavailable inhibitor of factor XIa. J Thromb Haemost 2022; 20:1400.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Piccini JP, Caso V, Connolly SJ, et al. Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study. Lancet 2022; 399:1383.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rao SV, Kirsch B, Bhatt DL, et al. A Multicenter, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Trial of the Oral Factor XIa Inhibitor Asundexian to Prevent Adverse Cardiovascular Outcomes After Acute Myocardial Infarction. Circulation 2022; 146:1196.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shoamanesh A, Mundl H, Smith EE, et al. Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial. Lancet 2022; 400:997.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Verhamme P, Yi BA, Segers A, et al. Abelacimab for Prevention of Venous Thromboembolism. N Engl J Med 2021; 385:609.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schaefer M, Buchmueller A, Dittmer F, et al. Allosteric Inhibition as a New Mode of Action for BAY 1213790, a Neutralizing Antibody Targeting the Activated Form of Coagulation Factor XI. J Mol Biol 2019; 431:4817.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weitz JI, Bauersachs R, Becker B, et al. Effect of Osocimab in Preventing Venous Thromboembolism Among Patients Undergoing Knee Arthroplasty: The FOXTROT Randomized Clinical Trial. JAMA 2020; 323:130.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhang H, Löwenberg EC, Crosby JR, et al. Inhibition of the intrinsic coagulation pathway factor XI by antisense oligonucleotides: a novel antithrombotic strategy with lowered bleeding risk. Blood 2010; 116:4684.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Büller HR, Bethune C, Bhanot S, et al. Factor XI antisense oligonucleotide for prevention of venous thrombosis. N Engl J Med 2015; 372:232.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Flaumenhaft R. Making (anti)sense of factor XI in thrombosis. N Engl J Med 2015; 372:277.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lorentz CU, Verbout NG, Wallisch M, et al. Contact Activation Inhibitor and Factor XI Antibody, AB023, Produces Safe, Dose-Dependent Anticoagulation in a Phase 1 First-In-Human Trial. Arterioscler Thromb Vasc Biol 2019; 39:799.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Al-Horani RA, Abdelfadiel EI, Afosah DK, et al. A synthetic heparin mimetic that allosterically inhibits factor XIa and reduces thrombosis in vivo without enhanced risk of bleeding. J Thromb Haemost 2019; 17:2110.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stassens P, Bergum PW, Gansemans Y, et al. Anticoagulant repertoire of the hookworm Ancylostoma caninum. Proc Natl Acad Sci U S A 1996; 93:2149.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Presta L, Sims P, Meng YG, et al. Generation of a humanized, high affinity anti-tissue factor antibody for use as a novel antithrombotic therapeutic. Thromb Haemost 2001; 85:379.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee A, Agnelli G, Büller H, et al. Dose-response study of recombinant factor VIIa/tissue factor inhibitor recombinant nematode anticoagulant protein c2 in prevention of postoperative venous thromboembolism in patients undergoing total knee replacement. Circulation 2001; 104:74.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Giugliano RP, Wiviott SD, Stone PH, et al. Recombinant nematode anticoagulant protein c2 in patients with non-ST-segment elevation acute coronary syndrome: the ANTHEM-TIMI-32 trial. J Am Coll Cardiol 2007; 49:2398.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hess CN, Capell WH, Bristow MR, et al. Rationale and design of a study to assess the safety and efficacy of rNAPc2 in COVID-19: the Phase 2b ASPEN-COVID-19 trial. Am Heart J 2022; 246:136.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Verhamme P, Tangelder M, Verhaeghe R, et al. Single intravenous administration of TB-402 for the prophylaxis of venous thromboembolism after total knee replacement: a dose-escalating, randomized, controlled trial. J Thromb Haemost 2011; 9:664.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carnemolla R, Patel KR, Zaitsev S, et al. Quantitative analysis of thrombomodulin-mediated conversion of protein C to APC: translation from in vitro to in vivo. J Immunol Methods 2012; 384:21.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moll S, Lindley C, Pescatore S, et al. Phase I study of a novel recombinant human soluble thrombomodulin, ART-123. J Thromb Haemost 2004; 2:1745.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kearon C, Comp P, Douketis J, et al. Dose-response study of recombinant human soluble thrombomodulin (ART-123) in the prevention of venous thromboembolism after total hip replacement. J Thromb Haemost 2005; 3:962.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chan MY, Cohen MG, Dyke CK, et al. Phase 1b randomized study of antidote-controlled modulation of factor IXa activity in patients with stable coronary artery disease. Circulation 2008; 117:2865.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cohen MG, Purdy DA, Rossi JS, et al. First clinical application of an actively reversible direct factor IXa inhibitor as an anticoagulation strategy in patients undergoing percutaneous coronary intervention. Circulation 2010; 122:614.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lincoff AM, Mehran R, Povsic TJ, et al. Effect of the REG1 anticoagulation system versus bivalirudin on outcomes after percutaneous coronary intervention (REGULATE-PCI): a randomised clinical trial. Lancet 2016; 387:349.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hagedorn I, Schmidbauer S, Pleines I, et al. Factor XIIa inhibitor recombinant human albumin Infestin-4 abolishes occlusive arterial thrombus formation without affecting bleeding. Circulation 2010; 121:1510.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang L, Essex DW. A new antithrombotic strategy: inhibition of the C-terminal active site of protein disulfide isomerase. J Thromb Haemost 2017; 15:770.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sousa HR, Gaspar RS, Sena EM, et al. Novel antiplatelet role for a protein disulfide isomerase-targeted peptide: evidence of covalent binding to the C-terminal CGHC redox motif. J Thromb Haemost 2017; 15:774.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zwicker JI, Schlechter BL, Stopa JD, et al. Targeting protein disulfide isomerase with the flavonoid isoquercetin to improve hypercoagulability in advanced cancer. JCI Insight 2019; 4.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Travers RJ, Shenoi RA, Kalathottukaren MT, et al. Nontoxic polyphosphate inhibitors reduce thrombosis while sparing hemostasis. Blood 2014; 124:3183.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 138700 Version 8.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34558200" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : First-in-human study of milvexian, an oral, direct, small molecule factor XIa inhibitor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35338177" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Safety, pharmacokinetics, and pharmacodynamics of milvexian in healthy Japanese participants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34780683" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Milvexian for the Prevention of Venous Thromboembolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34192419" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : First evaluation of the safety, pharmacokinetics, and pharmacodynamics of BAY 2433334, a small molecule targeting coagulation factor XIa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35596514" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Commentary on "Pharmacological profile of asundexian, a novel, orally bioavailable inhibitor of factor XIa": Small molecule factor XIa inhibitor asundexian allows for safer anticoagulation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35289054" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Pharmacological profile of asundexian, a novel, orally bioavailable inhibitor of factor XIa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35385695" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36030390" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : A Multicenter, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Trial of the Oral Factor XIa Inhibitor Asundexian to Prevent Adverse Cardiovascular Outcomes After Acute Myocardial Infarction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36063821" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34297496" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Abelacimab for Prevention of Venous Thromboembolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31655039" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Allosteric Inhibition as a New Mode of Action for BAY 1213790, a Neutralizing Antibody Targeting the Activated Form of Coagulation Factor XI.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31935028" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Effect of Osocimab in Preventing Venous Thromboembolism Among Patients Undergoing Knee Arthroplasty: The FOXTROT Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20807891" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Inhibition of the intrinsic coagulation pathway factor XI by antisense oligonucleotides: a novel antithrombotic strategy with lowered bleeding risk.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25482425" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Factor XI antisense oligonucleotide for prevention of venous thrombosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25482334" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Making (anti)sense of factor XI in thrombosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30700130" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Contact Activation Inhibitor and Factor XI Antibody, AB023, Produces Safe, Dose-Dependent Anticoagulation in a Phase 1 First-In-Human Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31397071" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : A synthetic heparin mimetic that allosterically inhibits factor XIa and reduces thrombosis in vivo without enhanced risk of bleeding.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8700900" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Anticoagulant repertoire of the hookworm Ancylostoma caninum.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11307801" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Generation of a humanized, high affinity anti-tissue factor antibody for use as a novel antithrombotic therapeutic.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11435341" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Dose-response study of recombinant factor VIIa/tissue factor inhibitor recombinant nematode anticoagulant protein c2 in prevention of postoperative venous thromboembolism in patients undergoing total knee replacement.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17599602" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Recombinant nematode anticoagulant protein c2 in patients with non-ST-segment elevation acute coronary syndrome: the ANTHEM-TIMI-32 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34986394" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Rationale and design of a study to assess the safety and efficacy of rNAPc2 in COVID-19: the Phase 2b ASPEN-COVID-19 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21284801" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Single intravenous administration of TB-402 for the prophylaxis of venous thromboembolism after total knee replacement: a dose-escalating, randomized, controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22750541" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Quantitative analysis of thrombomodulin-mediated conversion of protein C to APC: translation from in vitro to in vivo.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15456485" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Phase I study of a novel recombinant human soluble thrombomodulin, ART-123.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15869592" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Dose-response study of recombinant human soluble thrombomodulin (ART-123) in the prevention of venous thromboembolism after total hip replacement.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18506005" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Phase 1b randomized study of antidote-controlled modulation of factor IXa activity in patients with stable coronary artery disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20660806" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : First clinical application of an actively reversible direct factor IXa inhibitor as an anticoagulation strategy in patients undergoing percutaneous coronary intervention.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26547100" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Effect of the REG1 anticoagulation system versus bivalirudin on outcomes after percutaneous coronary intervention (REGULATE-PCI): a randomised clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20308613" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Factor XIIa inhibitor recombinant human albumin Infestin-4 abolishes occlusive arterial thrombus formation without affecting bleeding.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28109037" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : A new antithrombotic strategy: inhibition of the C-terminal active site of protein disulfide isomerase.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28109047" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Novel antiplatelet role for a protein disulfide isomerase-targeted peptide: evidence of covalent binding to the C-terminal CGHC redox motif.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30652973" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Targeting protein disulfide isomerase with the flavonoid isoquercetin to improve hypercoagulability in advanced cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25202141" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Nontoxic polyphosphate inhibitors reduce thrombosis while sparing hemostasis.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
